Alevin Therapeutics Ltd was founded in March 2022 with the aim of developing safe and effective medicines for patients with life-threatening diseases. Alevin Therapeutics is a spin-out from the University of Nottingham and is developing a platform of novel small molecule RGD integrin inhibitors with superior drug-like qualities. The Nottingham University spin-out aims to develop assets for therapeutic applications based on their RGD Integrin platform; in particular idiopathic pulmonary fibrosis (IPF), liver and kidney disease and cancer. The most advanced programme is close to a development candidate which we seek to take forward as an inhaled IPF drug.
|Investment Portfolio||Fund Investment|
|Co-Investors||University of Nottingham|